Patients with HF, including those with concomitant COPD, benefit from treatment with BBs, and these drugs should be used to improve outcomes in these patients. However, not only are BBs not prescribed ...

prescription medicine Despite substantial advances in therapeutic options for HFrEF, significant gaps remain in the use of guideline-directed medical therapy in these patients. Heart failure affects ...

Please provide your email address to receive an email when new articles are posted on . Quadruple therapy feasible in nearly half of patients with HFrEF at discharge after a decompensated event.

Please provide your email address to receive an email when new articles are posted on . Low income and education level among patients hospitalized with HF with reduced ejection fraction were linked to ...

Swedish investigators looked at potassium levels and all-cause mortality in HFrEF patients at 30 days, 12 months, and 5 years. Over all 3 time frames, the sweet spot in terms of lowest hazard risk for ...

The academic partners in the VerICiguaT GlObal Study in Subjects with Heart Failure with Reduced EjectIon FrAction (VICTORIA) are pleased to announce that patient enrollment has begun. The study will ...

The rest is history. So, in a way, ICDs for primary prevention of sudden cardiac death in patients with HFrEF is old news, as is cardiac resynchronization therapy for HFrEF if you have a wide QRS left ...

In this study, outcomes were investigated among a cohort of patients with heart failure with reduced ejection fraction (HFrEF) who participated in a cardiac rehabilitation program post hospital ...

The SGLT2 inhibitor drug class solidified its role as a major, new treatment for patients who have heart failure with reduced ejection fraction and no diabetes, with results from a second large, ...

BOSTON, March 11, 2025 (GLOBE NEWSWIRE) -- Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat and currently incurable diseases by developing a ...

BOSTON, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing next-generation therapeutics, ...